
With last Friday’s release of Novo Nordisk’s quarterly report for 2021, the pharmaceutical firm chose to reveal the actual sales figures for obesity drug Wegovy for the first time.
According to these numbers, sales of the treatment have gradually increased since it was launched in June last year. In the first three months of the year, Wegovy passed the DKK 1bn (USD 141.5m) milestone, generating DKK 1.4bn (USD 198.1m) in sales.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app